<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02887352</url>
  </required_header>
  <id_info>
    <org_study_id>OGT_2014-1</org_study_id>
    <nct_id>NCT02887352</nct_id>
  </id_info>
  <brief_title>French Adaptation of the California Card Sorting Task (CCST) in Multiple Sclerosis</brief_title>
  <acronym>E3C-DIFSEP</acronym>
  <official_title>French Adaptation of the CCST (California Card Sorting Task). Comparison of 3 Packages to CCST With Multiple Sclerosis (MS) Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondation Ophtalmologique Adolphe de Rothschild</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fondation Ophtalmologique Adolphe de Rothschild</source>
  <brief_summary>
    <textblock>
      Cognitive impairment affects up to 65% of multiple sclerosis (MS) subjects, especially&#xD;
      executive functions. The California Card Sorting Task (CCST) assesses specific components of&#xD;
      problem-solving ability. There is currently no French version of this test. Reims&#xD;
      neurological department in collaboration with Rothschild Foundation has developed a French&#xD;
      adaptation of CCST. This version includes three cards packages with two alternate forms to&#xD;
      control practice effects (test-retest). In order to assess &quot;test-retest reliability&quot; we have&#xD;
      to verify the comparability of the three cards packages within one session in MS patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 2014</start_date>
  <completion_date type="Actual">January 2020</completion_date>
  <primary_completion_date type="Actual">January 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>CCST Test score</measure>
    <time_frame>baseline</time_frame>
    <description>comparison of the scores of the three versions of the test</description>
  </primary_outcome>
  <enrollment type="Actual">48</enrollment>
  <condition>Multiple Sclerosis</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>assessment of problem-solving ability</intervention_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        multiple sclerosis patients&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Multiple Sclerosis patients&#xD;
&#xD;
          -  age &gt; 18 years old&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Montreal Cognitive Assessment (MOCA) â‰¤20&#xD;
&#xD;
          -  psychiatric disease&#xD;
&#xD;
          -  no proficiency in the French language&#xD;
&#xD;
          -  opposition to participate in the study&#xD;
&#xD;
          -  no medical insurance coverage&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anne-Claire VIRET</last_name>
    <role>Study Director</role>
    <affiliation>Fondation OPH A de Rothschild</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Olivier GOUT, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fondation OPH A de Rothschild</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fondation Ophtalmologique Adolphe de Rothschild</name>
      <address>
        <city>Paris</city>
        <zip>75019</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>August 25, 2016</study_first_submitted>
  <study_first_submitted_qc>August 29, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 2, 2016</study_first_posted>
  <last_update_submitted>June 11, 2021</last_update_submitted>
  <last_update_submitted_qc>June 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

